Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FDJQ9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $69,965
Award facts
- Contract value 100% obligated
- $69,964.72 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $69,964.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda (pembrolizumab) 100 mg/4 mL vials. The delivery order, issued on January 29, 2026, with an ultimate completion date of February 20, 2026, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award was funded by the Defense Logistics Agency and represents a routine supply transaction for oncology medications supporting Department of Defense healthcare operations.
This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply to military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and valued at $499,999,999, was awarded to DMS Pharmaceutical Group on November 13, 2025, with a performance period extending through December 31, 2036. The contractor's portfolio spans branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals, positioning it as a critical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FDJQ9?
SPE2DR26FDJQ9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FDJQ9 worth?
The government has obligated $69,965 on SPE2DR26FDJQ9.
Is contract SPE2DR26FDJQ9 an order under another contract?
Yes. SPE2DR26FDJQ9 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJQ9 competed?
The extent of competition for SPE2DR26FDJQ9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award